Oncotelic Therapeutics, Inc. financial data

Symbol
OTLC on OTC
Location
Aguora Hills, CA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 17 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.6% % 81%
Debt-to-equity 232% % 41%
Return On Equity -22% % 49%
Return On Assets -6.2% % 61%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 440,778,404 shares
Common Stock, Shares, Outstanding 439,446,318 shares 7.9%
Common Stock, Value, Issued $4,394,463 USD 7.9%
Weighted Average Number of Shares Outstanding, Basic 426,435,213 shares 4.7%
Weighted Average Number of Shares Outstanding, Diluted 452,809,058 shares 13%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $689,686 USD 55%
Operating Income (Loss) $689,494 USD 81%
Nonoperating Income (Expense) $1,233,150 USD 4.8%
Net Income (Loss) Attributable to Parent $1,669,158 USD 64%
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $409,000 USD 174%
Accounts Receivable, after Allowance for Credit Loss, Current $3,976 USD -79%
Assets, Current $1,612,948 USD 575%
Goodwill $2,788,230 USD 0%
Assets $28,156,163 USD 5.1%
Liabilities, Current $20,079,663 USD 23%
Liabilities $20,079,663 USD 7.7%
Retained Earnings (Accumulated Deficit) $39,108,893 USD -4.5%
Stockholders' Equity Attributable to Parent $9,050,578 USD 2.2%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest $8,076,500 USD -0.68%
Liabilities and Equity $28,156,163 USD 5.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $166,955 USD 28%
Net Cash Provided by (Used in) Financing Activities $160,000 USD -36%
Common Stock, Shares Authorized 750,000,000 shares 0%
Common Stock, Shares, Issued 439,446,318 shares 7.9%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $6,955 USD -137%
Interest Paid, Excluding Capitalized Interest, Operating Activities $94,773 USD 0%
Deferred Tax Assets, Valuation Allowance $12,760,000 USD -4.7%
Deferred Tax Assets, Gross $12,760,000 USD -4.7%
Deferred Tax Assets, Operating Loss Carryforwards $10,024,000 USD -4.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 15,000,000 shares 0%
Additional Paid in Capital $43,765,008 USD 3.7%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $0 USD
Interest Expense $885,217 USD -71%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%